Zogenix, Inc., a global biopharmaceutical company, has announced the pricing of its offering of US$200 million aggregate principal amount of 2.75% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. The issuance and sale of the notes are scheduled to settle on September 28, 2020, subject to customary closing conditions. Zogenix also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional US$30 million principal amount of notes.
Latham & Watkins LLP represented Zogenix in the offering with a capital markets team led by San Diego partners Cheston Larson and Matt Bush, with San Diego associates Anthony Gostanian, Jacob Steele, and Irene Fedoseienko. Advice was also provided on convertible debt matters by New York partner Greg Rodgers, with New York associates Andrew Blumenthal, Claire Solimine, and Jonathan Hernandez; and on tax matters by New York partners Bora Bozkurt and Elena Romanova, with New York associate Ron Moore.